Class of Stock [Axis] Series B Preferred Stock [Member] Equity Components [Axis] Series A Convertible Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Series C Convertible Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Antidilutive Securities [Axis] Equity Option [Member] Restricted Stock Units (RSUs) [Member] Warrant [Member] Title and Position [Axis] Directors and Officers Liability Insurance [Member] Plan Name [Axis] 2016 Stock Incentive Plan [Member] 2025 Stock Incentive Plan and Option Grants [Member] Related Party Transaction [Axis] Directors and executive officers [Member] Award Type [Axis] Perfromance Contingent Stock Options [Member] Related and Nonrelated Parties [Axis] Key employees and director [Member] Unvested employee and non-employee awards [Member] Statement of Income Location, Balance [Axis] General and Administrative Expense [Member] Exercise Price Range [Axis] $ 8.29 [Member] $ 108.00 [Member] $ 4050.00 [Member] $ 8,437.50 [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Product and Service [Axis] AL001 Licenses [Member] Guaranteed Insurance Contract, Type of Guarantee [Axis] First anniversary [Member] Second anniversary [Member] Third anniversary [Member] ALZN002 License [Member] Additional AL001 Licenses [Member] License Events [Axis] Pre Ind Meeting [Member] IND application filing [Member] Upon First Dosing Of Patient In Clinical Trial [Member] Upon Completion Of First Clinical Trial [Member] Upon First Patient Treated In A Phase I I I Clinical [Member] Upon Fda Nda Approval [Member] Upon IND application [Member] Upon First Dosing Of Patient In First Phase I Clinical Trial [Member] Upon completion of first Phase IIB clinical trial [Member] Upon First Patient Treated In Phase III Clinical Trial [Member] Upon first commercial sale [Member] Upon first patient treated in a Phase III clinical trial [Member] First commercial sale [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Securities Purchase Agreements [Member] Legal Entity [Axis] Ault Lending [Member] Series C Preferred Stock [Member] Orchid Finance [Member] Series A Preferred Stock [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Sales Agreement [Member] Counterparty Name [Axis] ATM Offering [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement [Table] Statement [Line Items] ASSETS CURRENT ASSETS Cash Prepaid expenses and other current assets TOTAL CURRENT ASSETS Property and equipment, net TOTAL ASSETS LIABILITIES AND STOCKHOLDERS’ EQUITY CURRENT LIABILITIES Accounts payable and accrued liabilities TOTAL LIABILITIES, ALL CURRENT COMMITMENTS AND CONTINGENCIES STOCKHOLDERS’ EQUITY Preferred Stock, Value Common stock, $0.0001 par value: 300,000,000 shares authorized; 3,804,741 and 778,733 issued and outstanding as of January 31, 2026 and April 30, 2025, respectively Additional paid-in capital Accumulated deficit TOTAL STOCKHOLDERS’ EQUITY TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY Preferred stock, par value (in dollars per share) Preferred stock shares designated Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value (in dollars per share) Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] OPERATING EXPENSES Research and development General and administrative Total operating expenses Loss from operations OTHER EXPENSE, NET Interest expense Total other expense, net NET LOSS Dividends on preferred shares NET LOSS AVAILABLE TO COMMON SHARES Basic net loss per common share Diluted net loss per common share Basic weighted average common shares outstanding Diluted weighted average common shares outstanding Beginning balance, value Beginning balance, shares Issuance of preferred stock for cash, net of issuance costs Issuance of preferred stock for cash, net of issuance costs, shares Conversion of preferred stock to common stock Conversion of preferred stock to common stock, shares Issuance of common stock for cash, net of issuance costs Issuance of common stock for cash, net of issuance costs, shares Issuance of common stock for restricted stock awards Issuance of common stock for restricted stock awards, shares Issuance of preferred stock for cash Issuance of preferred stock for cash, shares Conversion of note payable and interest to preferred stock Stock-based compensation to employees and consultants Preferred Series A dividend Net loss Ending balance, value Ending balance, shares Statement of Cash Flows [Abstract] Cash flows from operating activities: Net loss Adjustments to reconcile net loss to net cash used in operating activities: Depreciation expense Interest expense - debt discount Stock-based compensation to employees and consultants Changes in operating assets and liabilities: Prepaid expenses and other current assets Accounts payable and accrued liabilities Net cash used in operating activities Cash flows from investing activities: Purchase of equipment Net cash used in investing activities Cash flows from financing activities: Net proceeds from the issuance of common stock Net proceeds from the issuance of preferred stock Net cash provided by financing activities Net (decrease) increase in cash Cash at beginning of period Cash at end of period Supplemental disclosures of cash flow information: Non-cash financing activities: Conversion of Series A convertible preferred stock Conversion of Series B convertible preferred stock Conversion of Series C convertible preferred stock Fair value of warrants issued in connection with Series A convertible preferred stock Series A convertible preferred stock dividends Conversion of note payable and accrued interest into Series B convertible preferred stock Accounting Policies [Abstract] DESCRIPTION OF BUSINESS Organization, Consolidation and Presentation of Financial Statements [Abstract] LIQUIDITY AND GOING CONCERN SIGNIFICANT ACCOUNTING POLICIES Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] PREPAID EXPENSES AND OTHER CURRENT ASSETS Share-Based Payment Arrangement [Abstract] STOCK-BASED COMPENSATION Warrants WARRANTS Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Equity [Abstract] EQUITY TRANSACTIONS Subsequent Events [Abstract] SUBSEQUENT EVENTS Insider Trading Arrangements [Line Items] Rule 10b5-1 Arrangement Adopted [Flag] Non-Rule 10b5-1 Arrangement Adopted [Flag] Rule 10b5-1 Arrangement Terminated [Flag] Non-Rule 10b5-1 Arrangement Terminated [Flag] Basis of Presentation Accounting Estimates Cash and Cash Equivalents Fair Value of Financial Instruments Property and Equipment, Net Research and Development Expenses Stock-Based Compensation Warrants Loss per Common Share Preferred Stock Classification Segment Reporting Recent Accounting Standards Schedule of antidilutive securities excluded from computation of earnings per share Schedule of prepaid expenses and other current assets Schedule of stock option activity Schedule of stock-based compensation Schedule of warrant activity Schedule of common stock warrants outstanding Schedule of contractual obligation, fiscal year maturity Cash Working capital Accumulated deficit Stockholders' equity Net loss Cash used in operating activities Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of earnings per share, amount Cash equivalents Prepaid clinical trial expenses Prepaid insurance Other prepaid expenses Total prepaid expenses and other current assets Insurance purchased Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Shares available for grant begining (in shares) Number of shares begining (in shares) Weighted average exercise price begining (in dollars per share) Weighted average remaining contractual life Aggregate intrinsic value begining Aggregate intrinsic value begining Shares available for grant, options granted Number of shares, options granted Weighted average exercise price, options granted Shares available for grant, options exercised Number of shares, options exercised Weighted average exercise price, options exercised Shares available for grant, options expired Number of shares, options expired Weighted average exercise price, options expired Shares available for grant end (in shares) Number of shares end (in shares) Weighted average exercise price end (in dollars per share) Aggregate intrinsic value end Number of shares, options vested and expected to vest at end Weighted average exercise price, options vested and expected to vest at end Weighted average remaining contractual life, options vested and expected to vest at end Aggregate intrinsic value, options vested and expected to vest at end Number of shares, options exercisable at end Weighted average exercise price, options exercisable at end Weighted average remaining contractual life, options exercisable at end Aggregate intrinsic value, options exercisable at end Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Stock-Based Compensation Expense Share-based compensation arrangement by share-based payment award, number of shares authorized Share-based compensation arrangement by share-based payment award, number of additional shares authorized Share-based compensation arrangement by share-based payment award, expiration period Securities purchase & exchange agreement description Number of common stock sold Exercise price Options granted Terms of award Unamortized stock-based compensation expense related to unvested employee and non-employee awards Weighted-average period Number of outstanding, Cancelled/Expired Weighted Average Exercise Price, Cancelled/Expired Share-Based Payment Arrangement, Option, Exercise Price Range [Table] Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] Exercse price (in dollars per share) Number Outstanding Weighted average remaining contractual life (years) Warrant outstanding, weighted average exercise price (in dollars per share) Number of warrant exercisable Warrant exercisable, weighted average exercise price (in dollars per share) Product Liability Contingency [Table] Product Liability Contingency [Line Items] Payment Other Commitments, Description Percentage of royalty payments on net sales of product Description of licenses agreements Initial license fees Payments for royalties Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Preferred stock, shares authorized Number of shares purchase Termination loans description Sale of stock, number of shares issued Sale of stock, net proceeds Exercise price (in dollars per share) Number of warrants purchase Cancellations of cash advances Subscription receivable Converted shares Number of shares issued Fair market value of warrants Subsequent Event [Table] Subsequent Event [Line Items] Aggregate offering price The element represents perfromance contingent stock options member. The element represents key employees and director member. The element represents exercise price1 member. The element represents exercise price2 member. The element represents exercise price3 member. The element represents exercise price4 member. The element represents class of warrant or right weighted average exercise price of warrants or rights. The element represents class of warrant or right exercisable. The element represents class of warrant or right exercisable weighted average exercise price. The element represents percentage of royalty payments on net sales of product.. The element represents a l001 license member. Amount of initial license fees. The element represents additional a l001 license member. The element represents license events axis. The element represents pre ind meeting member. The element represents number of shares purchase. The element represents securities purchase agreements member. Assets, Current Assets Liabilities Equity, Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) Interest Expense, Operating and Nonoperating Nonoperating Income (Expense) Net Income (Loss) Attributable to Parent DividendsOnPreferredShares Net Income (Loss) Available to Common Stockholders, Basic Shares, Outstanding Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Share-Based Payment Arrangement, Noncash Expense Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Accounts Payable and Accrued Liabilities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Payments to Acquire Machinery and Equipment Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Commitments and Contingencies Disclosure [Text Block] WarrantsPolicyTextBlock Cash [Default Label] Retained Earnings, Appropriated NetLoss Prepaid Expense and Other Assets Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period